{"id":11534,"date":"2025-11-30T01:34:52","date_gmt":"2025-11-30T00:34:52","guid":{"rendered":"https:\/\/oxfordwisefinance.com\/blog\/?p=11534"},"modified":"2025-11-30T01:35:00","modified_gmt":"2025-11-30T00:35:00","slug":"buy-this-pharmaceutical-stock-that-just-jumped-3-8","status":"publish","type":"post","link":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/","title":{"rendered":"Buy This Pharmaceutical Stock That Just Jumped 3.8%"},"content":{"rendered":"<\/p>\n<p>The struggling pharmaceutical giant is showing signs of life.<\/p>\n<div id=\"article-body\">\n<p>Over the past 18 months, <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/10b-deal-boosts-mercks-respiratory-prospects-with-verona-pharma\/\">Merck<\/a><\/b> <span class=\"ticker-mention inline-flex items-center font-bold\" data-id=\"204567\">(MRK <span class=\"ml-1 text-green-900\">+0.20%<\/span>)<\/span> shares have faced significant challenges, primarily due to various headwinds impacting performance. The <b>vaccine business<\/b> has underperformed, leading to lower-than-expected revenue growth. Moreover, a rising number of mid- and late-stage clinical candidates present potential threats to the market dominance of <b>Keytruda<\/b>, Merck\u2019s blockbuster <b>cancer drug<\/b>. These factors have contributed to a decline in stock performance, raising concerns among investors.<\/p>\n<p>Nonetheless, Merck has been diligently working to overcome these challenges. Recent developments have positively impacted the company\u2019s prospects and share price, instilling a renewed sense of optimism. Let\u2019s explore what these developments entail and their implications for potential investors.<\/p>\n<h2 class=\"my-6 text-2xl font-bold\">Merck Achieves a Significant Mid-Stage Victory<\/h2>\n<p>In 2021, Merck made a strategic move by acquiring <b>Acceleron Pharma<\/b>, a smaller <b>biotechnology company<\/b>, for an impressive $11.5 billion. The key asset from this acquisition was <b>sotatercept<\/b>, which was under investigation as a treatment for <b>pulmonary hypertension<\/b> (PH), a serious condition characterized by high blood pressure in the lungs.<\/p>\n<p>Since its acquisition, sotatercept has received regulatory approval and is now marketed under the brand name <b>Winrevair<\/b>. It is specifically indicated for treating a type of PH known as <b>pulmonary arterial hypertension<\/b> (PAH), which occurs when blood flow in the lungs is obstructed due to narrowed blood vessels. Winrevair has shown promising results, generating approximately $976 million in revenue within the first nine months of 2025 alone.<\/p>\n<div class=\"image\"><img decoding=\"async\" alt=\"Doctor and patient talking.\" loading=\"lazy\" width=\"880\" height=\"587\" data-nimg=\"1\" class=\"h-auto max-w-full rounded object-contain\" style=\"color:transparent\" src=\"https:\/\/g.foolcdn.com\/image\/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F843501%2Fpatient-talking-with-a-physician.jpg&amp;w=3840&amp;op=resize\" \/><\/p>\n<p class=\"caption\">Image source: Getty Images.<\/p>\n<\/div>\n<p>Looking ahead, additional developments for sotatercept are promising. Merck recently shared that sotatercept has successfully completed a phase 2 study involving patients with combined post- and precapillary pulmonary hypertension (CpcPH) related to heart failure with preserved ejection fraction (HFpEF). Essentially, this condition arises when patients experience two causes of PH simultaneously, representing a subset of Group 2 PH, which is one of the more prevalent forms of the disease.<\/p>\n<p>This mid-stage victory is crucial for Merck. Although CpcPH due to HFpEF is classified as rare, it is often underdiagnosed, with no specific treatments currently approved for it. Thus, Merck is strategically targeting a niche market where it may not face intense competition if sotatercept successfully navigates phase 3 studies and secures the necessary label expansion.<\/p>\n<p>Even though the patient population is around 100,000 individuals, which aligns with the definition of &#8220;rare,&#8221; the potential for significant success in this indication is substantial. Analysts estimate that this could enhance the annual sales potential of sotatercept by over $1 billion. Consequently, Merck\u2019s stock experienced a surge following this news, indicating investor confidence. While competition may arise, whether from biosimilars or other sources, the progress of sotatercept demonstrates promising potential for Merck to maintain its competitive edge.<\/p>\n<h2 class=\"my-6 text-2xl font-bold\">Additional Positive Developments for Merck<\/h2>\n<p>Several other favorable developments further enhance Merck&#8217;s outlook. Let\u2019s explore two noteworthy advancements.<\/p>\n<p>Firstly, Merck has announced its intention to acquire <b>Cidara Therapeutics<\/b> <span class=\"ticker-mention inline-flex items-center font-bold\" data-id=\"335079\">(CDTX <span class=\"ml-1 text-green-900\">+0.06%<\/span>)<\/span>, a mid-cap biotech company, for approximately $9.2 billion in cash. This acquisition will provide Merck access to CD388, a potential therapy that has the capacity to disrupt the <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/3-revolutionary-stocks-id-buy-right-now-without-hesitation\/\">influenza vaccine market<\/a><\/b>. Existing flu vaccines have significant limitations, including reduced efficacy over the course of the season and diminished effectiveness in vulnerable populations such as the elderly and immunocompromised individuals.<\/p>\n<p>CD388 aims to address these critical shortcomings. It has shown promising results in phase 2 studies and could emerge as a vital addition to Merck&#8217;s expanding portfolio, further solidifying its position in the market.<\/p>\n<section class=\"shadow-card mb-[40px] border border-gray-300\">\n<div class=\"flex flex-wrap place-content-between\">\n<div class=\"flex w-full place-items-center lg:w-3\/4\">\n<div class=\"py-4 pr-4\"><img decoding=\"async\" alt=\"Merck Stock Quote\" loading=\"lazy\" width=\"64\" height=\"64\" data-nimg=\"1\" class=\"w-full flex-none object-contain\" style=\"color:transparent\" src=\"https:\/\/g.foolcdn.com\/image\/?url=https%3A%2F%2Fg.foolcdn.com%2Fart%2Fcompanylogos%2Fmark%2FMRK.png&amp;w=128&amp;op=resize\" \/><\/div>\n<\/div>\n<div class=\"flex w-full place-items-center lg:w-1\/4\">\n<div class=\"h-full w-5\/6 px-4 py-2.5 lg:text-right bg-green-200\">\n<p>Today&#8217;s Change<\/p>\n<p>(<!-- -->0.20<!-- -->%) $<!-- -->0.21<\/p>\n<p>Current Price<\/p>\n<p>$<!-- -->104.84<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"flex flex-wrap overflow-hidden transition-all duration-300 h-0\">\n<div class=\"w-full p-2 lg:w-1\/4 lg:p-4\">\n<h3 class=\"text-gray-1100 text-md my-[22px] leading-snug font-bold uppercase\">Key Data Points<\/h3>\n<div class=\"text-gray-1100 my-[14px] grid grid-cols-2 text-sm\">\n<p>Market Cap<\/p>\n<p>$260B<\/p>\n<p>Day&#8217;s Range<\/p>\n<p>$<!-- -->104.13<!-- --> &#8211; $<!-- -->105.41<\/p>\n<p>52wk Range<\/p>\n<p>$<!-- -->73.31<!-- --> &#8211; $<!-- -->105.84<\/p>\n<p>Volume<\/p>\n<p>229K<\/p>\n<p>Avg Vol<\/p>\n<p>13M<\/p>\n<p>Gross Margin<\/p>\n<p>75.81<!-- -->%<\/p>\n<p>Dividend Yield<\/p>\n<p>3.09<!-- -->%<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/section>\n<p>Secondly, Merck is nearing another exciting launch. The company is currently studying a combination of <b>doravirine<\/b> and <b>islatravir<\/b> for the treatment of <b>HIV<\/b> and is awaiting approval from the <b><a href=\"https:\/\/oxfordwisefinance.com\/blog\/finance-docket-the-financial-and-business-implications-of-marijuana-reclassification\/\">U.S. Food and Drug Administration<\/a><\/b>, which is expected to occur early next year. This product could play a significant role in Merck&#8217;s strategy following the anticipated peak of Keytruda sales.<\/p>\n<p>Additionally, it is noteworthy that Merck has recently received approval for a subcutaneous version of Keytruda. While this new formulation does not encompass all the indications of the original version, it will help mitigate the risks associated with an impending patent cliff. As Merck integrates the subcutaneous Keytruda with innovative products like Winrevair, its forthcoming HIV treatment, and Capvaxive\u2014a pneumonia vaccine that received approval last year and generated $244 million in sales during the third quarter\u2014it is well-positioned to navigate the challenges facing its core franchise.<\/p>\n<h2 class=\"my-6 text-2xl font-bold\">Should You Consider Investing in Merck Stock?<\/h2>\n<p>As Merck continues to face challenges related to its <b>vaccine business<\/b>, the drugmaker is demonstrating resilience by showcasing its historical performance. The company\u2019s robust pipeline and keen ability to identify promising opportunities suggest that it is likely to thrive over the long term, despite the obstacles it faces.<\/p>\n<p>Moreover, Merck stands out as a strong dividend stock, having increased its payouts by an impressive 84.7% over the past decade, currently offering a forward yield of 3.5%. While it may not be the go-to stock for explosive growth, Merck is an excellent, reliable blue-chip income stock that deserves a place in any well-rounded investment portfolio.<\/p>\n<\/div>\n\n<p><a href=\"https:\/\/www.fool.com\/investing\/2025\/11\/29\/should-you-buy-this-blue-chip-pharmaceutical-stock\/\" rel=\"nofollow\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The struggling pharmaceutical giant is showing signs of life. Over the past [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":11535,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","pagelayer_contact_templates":[],"_pagelayer_content":"","iawp_total_views":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[142,240],"tags":[],"class_list":["post-11534","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-finance-business","category-stock-market","col-md-12"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance<\/title>\n<meta name=\"description\" content=\"The struggling pharmaceutical giant is showing signs of life.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance\" \/>\n<meta property=\"og:description\" content=\"The struggling pharmaceutical giant is showing signs of life.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/\" \/>\n<meta property=\"og:site_name\" content=\"Blog - Oxford Wise Finance\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/instantpaydayloans\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-30T00:34:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-30T00:35:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Oxfordwisefinance\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@https:\/\/x.com\/OxfordWiseLoans\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/\"},\"author\":{\"name\":\"Oxfordwisefinance\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"headline\":\"Buy This Pharmaceutical Stock That Just Jumped 3.8%\",\"datePublished\":\"2025-11-30T00:34:52+00:00\",\"dateModified\":\"2025-11-30T00:35:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/\"},\"wordCount\":854,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1\",\"articleSection\":[\"Finance &amp; Business\",\"Stock Market\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/\",\"name\":\"Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1\",\"datePublished\":\"2025-11-30T00:34:52+00:00\",\"dateModified\":\"2025-11-30T00:35:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\"},\"description\":\"The struggling pharmaceutical giant is showing signs of life.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/oxfordwisefinance.com\\\/blog\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1\",\"width\":1200,\"height\":800,\"caption\":\"Doctor and patient talking.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Buy This Pharmaceutical Stock That Just Jumped 3.8%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#website\",\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/\",\"name\":\"Blog - Oxford Wise Finance\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/#\\\/schema\\\/person\\\/86a546d6182e892aecd0194cf5ec4e36\",\"name\":\"Oxfordwisefinance\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g\",\"caption\":\"Oxfordwisefinance\"},\"sameAs\":[\"https:\\\/\\\/oxfordwisefinance.com\\\/\",\"https:\\\/\\\/www.facebook.com\\\/instantpaydayloans\",\"https:\\\/\\\/x.com\\\/https:\\\/\\\/x.com\\\/OxfordWiseLoans\"],\"url\":\"https:\\\/\\\/oxfordwisefinance.com\\\/blog\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance","description":"The struggling pharmaceutical giant is showing signs of life.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/","og_locale":"en_US","og_type":"article","og_title":"Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance","og_description":"The struggling pharmaceutical giant is showing signs of life.","og_url":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/","og_site_name":"Blog - Oxford Wise Finance","article_author":"https:\/\/www.facebook.com\/instantpaydayloans","article_published_time":"2025-11-30T00:34:52+00:00","article_modified_time":"2025-11-30T00:35:00+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","type":"image\/jpeg"}],"author":"Oxfordwisefinance","twitter_card":"summary_large_image","twitter_creator":"@https:\/\/x.com\/OxfordWiseLoans","twitter_misc":{"Written by":false,"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#article","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/"},"author":{"name":"Oxfordwisefinance","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"headline":"Buy This Pharmaceutical Stock That Just Jumped 3.8%","datePublished":"2025-11-30T00:34:52+00:00","dateModified":"2025-11-30T00:35:00+00:00","mainEntityOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/"},"wordCount":854,"commentCount":0,"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","articleSection":["Finance &amp; Business","Stock Market"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/","url":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/","name":"Buy This Pharmaceutical Stock That Just Jumped 3.8% - Blog - Oxford Wise Finance","isPartOf":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#primaryimage"},"image":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","datePublished":"2025-11-30T00:34:52+00:00","dateModified":"2025-11-30T00:35:00+00:00","author":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36"},"description":"The struggling pharmaceutical giant is showing signs of life.","breadcrumb":{"@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#primaryimage","url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","contentUrl":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","width":1200,"height":800,"caption":"Doctor and patient talking."},{"@type":"BreadcrumbList","@id":"https:\/\/oxfordwisefinance.com\/blog\/buy-this-pharmaceutical-stock-that-just-jumped-3-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/oxfordwisefinance.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Buy This Pharmaceutical Stock That Just Jumped 3.8%"}]},{"@type":"WebSite","@id":"https:\/\/oxfordwisefinance.com\/blog\/#website","url":"https:\/\/oxfordwisefinance.com\/blog\/","name":"Blog - Oxford Wise Finance","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/oxfordwisefinance.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/oxfordwisefinance.com\/blog\/#\/schema\/person\/86a546d6182e892aecd0194cf5ec4e36","name":"Oxfordwisefinance","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f667a5981709cbc3507f5111795ee16c30dedbc973de1dd352401e60a03e4e9e?s=96&d=identicon&r=g","caption":"Oxfordwisefinance"},"sameAs":["https:\/\/oxfordwisefinance.com\/","https:\/\/www.facebook.com\/instantpaydayloans","https:\/\/x.com\/https:\/\/x.com\/OxfordWiseLoans"],"url":"https:\/\/oxfordwisefinance.com\/blog\/author\/admin\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/oxfordwisefinance.com\/blog\/wp-content\/uploads\/2025\/11\/Should-You-Buy-This-Blue-Chip-Pharmaceutical-Stock-That-Just.jpgw1200opresize.jpeg?fit=1200%2C800&ssl=1","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/comments?post=11534"}],"version-history":[{"count":1,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11534\/revisions"}],"predecessor-version":[{"id":11536,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/posts\/11534\/revisions\/11536"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media\/11535"}],"wp:attachment":[{"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/media?parent=11534"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/categories?post=11534"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/oxfordwisefinance.com\/blog\/wp-json\/wp\/v2\/tags?post=11534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}